HOUSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH ), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, August 10, 2016 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2016, and to provide a business overview.
To access the live conference call, please call (844) 260-6671 (domestic) or (508) 915-0912 (international) at least five minutes prior to the start time, and refer to conference ID 52615237. A live audio webcast of the call will also be available on the Investors’ section of the Company’s website, www.biopathholdings.com . An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is being readied for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com .
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
